Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity
NCT07594093
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This study will test a study drug called REGN20934 to see how safe and well tolerated this drug is, as well as how the drug is processed in the body for participants with overweight or obesity. The study is looking at: What side effects REGN20934 might cause How much REGN20934 is in the blood at different times If the body makes antibodies to REGN20934
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Overweight or Obesity
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Regeneron Pharmaceuticals
- Last updated on ClinicalTrials.gov
- September 25, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Parexel International · Glendale, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.